1. Home
  2. PGP vs CGTX Comparison

PGP vs CGTX Comparison

Compare PGP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PGP

Pimco Global StocksPlus & Income Fund of Beneficial Interest

HOLD

Current Price

$8.58

Market Cap

100.5M

Sector

Finance

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.00

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGP
CGTX
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.5M
102.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PGP
CGTX
Price
$8.58
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
50.1K
2.6M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
10.84%
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.04
$0.55
52 Week High
$9.41
$3.83

Technical Indicators

Market Signals
Indicator
PGP
CGTX
Relative Strength Index (RSI) 47.11 40.43
Support Level $8.35 $0.55
Resistance Level $8.70 $1.19
Average True Range (ATR) 0.10 0.08
MACD -0.01 -0.01
Stochastic Oscillator 28.24 18.81

Price Performance

Historical Comparison
PGP
CGTX

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: